|
Can’t access the links? Add “lnks.gd” to the allowlist of your content blocking software. |
|
|
Effective April 1, 2025 Washington Apple Health (Medicaid) will make a significant change to the preferred products in the Cytokine and CAM Antagonist drug class. Brand name Humira products will no longer be preferred. Select adalimumab biosimilars (see link for a list for specific products), Enbrel, Enbrel Sureclick and Spevigo will be the preferred products in this class.
This change will apply to all agency-contracted managed care organizations (MCOs) and the fee-for-service (FFS) program per the Apple Health PDL
|
|
|
For questions about the Apple Health PDL, please email Apple Health Pharmacy
|
|
|
|